CAPR
CAPRICOR THERAPEUTICS, INC.
NASDAQ · Healthcare · Biotechnology · US
$9.06
−3.82%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$9.30
From 52W high−74.36%
Volume3.24M
Market cap$526.74M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$9.30
From 52W high
−74.36%
Volume
3.24M
Market cap
$526.74M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.3x
P/E (TTM)
—
RSI (14)
49.7
MomentumView details →
1D Return
−3.82%
YTD Return
−68.33%
SummaryUpdated Jun 1, 2026
Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company founded in 2005 and headquartered in San Diego, California. The company went public in 2007 and focuses on developing transformative cell and exosome-based therapeutics for treating various diseases and disorders. Capricor is primarily known for its lead candidate <b>deramiocel</b> (formerly CAP-1002), an allogeneic cardiac-derived cell therapy that has completed Phase III clinical trials for treating late-stage Duchenne muscular dystrophy (DMD). The company has submitted a Biologics License Application (BLA) to the FDA for deramiocel, with a priority review PDUFA date of August 31, 2025.
Similar companies
Latest newsMore news →
The Shareholders Foundation announced that a lawsuit was filed on behalf of certain investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR).5d agoKaplan Fox & Kilsheimer LLP announced that a class action lawsuit has been filed against Capricor Therapeutics, Inc. on behalf of investors who acquired Capricor securities between December 17, 2025 and July 26, 2026.9d agoThe DJS Law Group reminded investors of a class action lawsuit against Capricor Therapeutics, Inc. for alleged violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5.9d ago